ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Antibiotics

Melinta will acquire antibiotics developer Tetraphase

by Michael McCoy
June 13, 2020 | APPEARED IN VOLUME 98, ISSUE 23

 

The third time’s the charm for the antibiotic developer Tetraphase Pharmaceuticals. It has agreed to be purchased by Melinta Therapeutics for $39 million and up to $16 million more.Tetraphase struck a $14 million deal in March to be bought by AcelRx. Then in May, the firm said it was considering a $22 million offer from La Jolla Pharmaceutical. Tetraphase has amassed more than $600 million in losses over the years as it developed its tetracycline Xervara.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment